Trial Profile
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Trametinib (Primary)
- Indications Haemangioendothelioma
- Focus Therapeutic Use
- 21 Sep 2023 Status changed from active, no longer recruiting to completed.
- 08 Jun 2021 The trial was amended after stage 1 to continue enrollment to 27 pts with TAZ-CAMTA1 detected by FISH with goal of >4 objective responses in this group
- 08 Jun 2021 Results (n=43)assessing effect of MEK inhibition using trametinib in pts with unresectable epithelioid hemangioendothelioma presented at the 57th Annual Meeting of the American Society of Clinical Oncology